RAGE Biotech Pty Ltd: Company Profile

Background

Overview

RAGE Biotech Pty Ltd is an Australian pharmaceutical start-up dedicated to developing innovative therapeutics targeting the Receptor for Advanced Glycation End-products (RAGE). Established in 2020, the company focuses on addressing chronic inflammatory diseases through precision RNA-targeting and therapeutic peptide technologies. Its mission is to improve the lives of individuals suffering from difficult-to-treat inflammatory conditions globally.

Mission and Vision

RAGE Biotech's mission is to harness cutting-edge RNA-targeting and therapeutic peptide technologies to develop effective RAGE inhibitors, aiming to enhance the lives of patients with chronic inflammatory diseases worldwide. The company's vision is to become a leader in precision medicine for chronic inflammation, offering transformative therapies that address unmet medical needs.

Primary Area of Focus

The company's primary focus is on developing novel therapeutics that modulate RAGE, a key receptor involved in the progression of various chronic inflammatory diseases, including chronic obstructive pulmonary disease (COPD), severe asthma, cystic fibrosis, and other lung conditions.

Industry Significance

RAGE Biotech operates within the biopharmaceutical industry, specializing in the development of RNA-based therapeutics. Its work is significant due to the potential of RAGE inhibitors to address chronic inflammatory diseases, a major global health concern affecting millions of individuals. The company's innovative approach positions it as a key player in the emerging field of RNA-targeted therapies for chronic inflammation.

Key Strategic Focus

Core Objectives

RAGE Biotech aims to develop precision RNA-targeted therapies that modulate RAGE activity, thereby reducing chronic inflammation and improving patient outcomes in various inflammatory diseases. The company's strategic objectives include advancing its lead program into clinical trials, expanding its therapeutic pipeline, and establishing partnerships to accelerate development and commercialization.

Specific Areas of Specialization

The company specializes in the development of splice-switching oligonucleotide (SSO) therapies, a novel class of RNA-targeted drugs. These SSOs are designed to modulate gene expression by altering RNA splicing, offering a precise mechanism to influence disease-related proteins. RAGE Biotech's expertise lies in applying this technology to target RAGE, a receptor implicated in the pathogenesis of various chronic inflammatory diseases.

Key Technologies Utilized

• RNA-Targeting Technologies: Utilizing SSOs to modulate gene expression by altering RNA splicing, thereby influencing protein production.

• Therapeutic Peptide Technologies: Developing peptides that can specifically interact with RAGE to modulate its activity.

Primary Markets or Conditions Targeted

RAGE Biotech primarily targets chronic inflammatory diseases, with an initial focus on respiratory conditions such as COPD, severe asthma, and cystic fibrosis. The company also explores potential applications in other inflammatory diseases affecting the liver, kidneys, and central nervous system.

Financials and Funding

Funding History

RAGE Biotech has secured funding through multiple rounds:

• Seed Funding (November 2021): The company raised $3.7 million in a seed funding round led by IP Group Australia, with support from Monash Investment Holdings. This capital was allocated to advance its lead program, an inhaled RNA therapeutic targeting lung diseases characterized by chronic inflammation.

• Series A Funding (November 2025): RAGE Biotech raised $29 million in a Series A funding round led by IP Group Australia and Hostplus, with continued participation from Monash Ventures. The funds are intended to support the advancement of the company's lead program, RB042, into first-in-human clinical trials.

Total Funds Raised

As of November 2025, RAGE Biotech has raised a total of $32.7 million across its seed and Series A funding rounds.

Notable Investors

• IP Group Australia: A venture capital firm specializing in the commercialization of intellectual property from universities and research institutions.

• Hostplus: An Australian superannuation fund that invests in various sectors, including biotechnology.

• Monash Ventures: The commercialization arm of Monash University, supporting the translation of research into commercial outcomes.

Intended Utilization of Capital

The capital raised is primarily allocated to:

• Advancing Lead Program: Progressing RB042, an inhaled RNA therapeutic, into first-in-human clinical trials for the treatment of COPD and other inflammatory lung diseases.

• Pipeline Expansion: Developing additional programs targeting other chronic inflammatory conditions affecting the liver, kidneys, and central nervous system.

• Operational Growth: Enhancing research and development capabilities, expanding the team, and establishing strategic partnerships to accelerate product development and commercialization.

Pipeline Development

Key Pipeline Candidates

• RB042: An inhaled splice-switching oligonucleotide (SSO) therapy targeting RAGE, currently in the final stages of preclinical development, with plans to enter Phase 1 clinical trials.

Stages of Clinical Trials or Product Development

• Preclinical Development: RB042 is in the final stages of preclinical development, preparing for initial human trials.

• Clinical Trials: The company plans to initiate Phase 1 clinical trials for RB042, focusing on safety and dosage in healthy volunteers.

Target Conditions

• Chronic Obstructive Pulmonary Disease (COPD): A progressive lung disease characterized by chronic inflammation and airflow obstruction.

• Severe Asthma: A form of asthma that is difficult to control and often requires high-dose inhaled corticosteroids.

• Cystic Fibrosis: A genetic disorder affecting the lungs and digestive system, leading to chronic respiratory infections and inflammation.

Relevant Timelines for Anticipated Milestones

• Preclinical Completion: Anticipated completion of preclinical studies and readiness for clinical trials in the near future.

• Clinical Trial Initiation: Plans to commence Phase 1 clinical trials for RB042, with timelines dependent on regulatory approvals and operational readiness.

Technological Platform and Innovation

Proprietary Technologies

• Splice-Switching Oligonucleotides (SSOs): A class of RNA-targeted drugs designed to modulate gene expression by altering RNA splicing, offering a precise mechanism to influence disease-related proteins.

• RAGE Modulation: Developing therapies that specifically target and modulate the activity of RAGE, a receptor implicated in various chronic inflammatory diseases.

Significant Scientific Methods

• RNA Splicing Modulation: Utilizing SSOs to correct or modify RNA splicing patterns, thereby restoring normal protein function and reducing disease-related inflammation.

• Inhaled Drug Delivery: Developing inhaled formulations of RNA therapeutics to directly target lung tissues, enhancing drug efficacy and minimizing systemic side effects.

Leadership Team

Executive Profiles

• Dr. Siro Perez: Chief Executive Officer

• Professional Background: With over 20 years in life sciences, Dr. Perez has held leadership roles at Novartis Pharma AG, The Boston Consulting Group, and Hadean Ventures. He holds a PhD in Molecular Biology and a Master’s in Finance from London Business School.

• Dr. Edwin Tucker: Chief Medical and Development Officer

• Professional Background: Dr. Tucker brings over 30 years of experience in the biopharmaceutical industry, including roles as CMO at Jasper Therapeutics. He is a member of the Royal College of Physicians (UK) and holds degrees in Pharmacology and Medicine from the University of Leeds, as well as an MBA from the University of Connecticut.

• Dr. Christopher Wraight: Chief Scientific Officer

• Professional Background: Dr. Wraight has extensive experience in the biotechnology sector, having co-founded RAGE Biotech and led its scientific strategy. He remains with the company as Chief Scientific Officer, focusing on scientific leadership and pipeline expansion.

Board of Directors

• Dr. Mike Molinari: Managing Director at IP Group Australia, joined the Board in November 2025.

Competitor Profile

Market Insights and Dynamics

The market for chronic inflammatory disease treatments is substantial, with millions of patients worldwide affected by conditions such as COPD, severe asthma, and cystic fibrosis. Competitors in this space are focused on developing novel therapies that can address the underlying inflammatory pathways, with an emphasis on precision medicine and innovative drug delivery technologies.

Competitive Landscape

Key competitors include established pharmaceutical companies and emerging biotech firms developing RNA-based therapeutics and peptide drugs targeting similar pathways. These competitors vary in their approaches, from small molecule inhibitors and monoclonal antibodies to next-generation oligonucleotide therapies.

Differentiation

RAGE Biotech differentiates itself by focusing specifically on the Receptor for Advanced Glycation End-products (RAGE) as a target, utilizing proprietary splice-switching oligonucleotide technology combined with therapeutic peptides. This dual-technology platform aims to offer highly specific and effective modulation of inflammatory responses, potentially improving safety and efficacy profiles relative to competitors.

Strategic Positioning

The company’s strategic advancement of its lead inhaled therapeutic RB042 into clinical trials, backed by significant funding and experienced leadership, places it competitively in the field. Additionally, its focus on difficult-to-treat respiratory inflammatory conditions and expansion plans into other chronic inflammatory diseases provide a broad platform for future growth.

Research and Development Focus

Competitor firms are also investing in early-stage research on RNA splicing modulation and inhaled delivery mechanisms, highlighting the growing importance of these technologies within the biopharmaceutical industry targeting chronic inflammation.

Industry Trends

The chronic inflammatory disease market is increasingly driven by innovations in nucleic acid therapeutics and precision targeting methods. The use of inhaled delivery systems to directly address respiratory conditions is a key trend enhancing drug efficacy while reducing systemic exposure.

Market Challenges

Challenges faced by competitors include regulatory hurdles, demonstrating clinical efficacy and safety, and the biological complexity of chronic inflammatory diseases. The competitive focus on innovative RNA therapeutics necessitates strong intellectual property positions and robust clinical validation.